Scinai Immunotherapeutics Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SCNI research report →
Companywww.scinai.com
Scinai Immunotherapeutics Ltd. , a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.
- CEO
- Amir Reichman
- IPO
- 2015
- Employees
- 31
- HQ
- Jerusalem, IL
Price Chart
Valuation
- Market Cap
- $628.09K
- P/E
- -0.13
- P/S
- 0.48
- P/B
- 0.14
- EV/EBITDA
- -0.19
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -201.84%
- Op Margin
- -574.00%
- Net Margin
- -632.23%
- ROE
- -98.32%
- ROIC
- -72.73%
Growth & Income
- Revenue
- $1.31M · 99.24%
- Net Income
- $-8,307,000 · -273.21%
- EPS
- $-3.60 · -160.00%
- Op Income
- $-7,542,000
- FCF YoY
- 4.60%
Performance & Tape
- 52W High
- $6.18
- 52W Low
- $0.44
- 50D MA
- $0.62
- 200D MA
- $1.02
- Beta
- 2.19
- Avg Volume
- 3.43M
Get TickerSpark's AI analysis on SCNI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Mark Elad | other | 0 |
| Mar 18, 26 | Mark Elad | other | 13,460,984 |
| Mar 18, 26 | MARGOLIN YAEL | other | 200,000 |
| Mar 18, 26 | MARGOLIN YAEL | other | 8,000,000 |
| Mar 18, 26 | MARGOLIN YAEL | other | 48,200,000 |
| Mar 18, 26 | Ben-Or Uri | other | 0 |
| Mar 18, 26 | Ben-Or Uri | other | 2,519,344 |
| Mar 18, 26 | Moed Samuel J | other | 200,000 |
| Mar 18, 26 | Moed Samuel J | other | 8,000,000 |
| Mar 18, 26 | Moed Samuel J | other | 48,200,000 |
Our SCNI Coverage
We haven't published any research on SCNI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SCNI Report →